These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 24837467)

  • 21. [JAK2V617F mutation in the patients with myeloproliferative disorder and its relation with clinical characteristics].
    Zhu JF; Liu Y; Liu P; Jia MF; Cheng J; Zhao L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Aug; 19(4):916-20. PubMed ID: 21867614
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Clinical study on relationship between JAK2 V617F mutation and chronic myeloproliferative disorders].
    Zhang Y; Li L; Nie L; Yu Y; Yang YH; Zhang ZQ; Yang L; Xu SC; Xiao ZJ
    Zhonghua Xue Ye Xue Za Zhi; 2008 Feb; 29(2):105-9. PubMed ID: 18681311
    [TBL] [Abstract][Full Text] [Related]  

  • 23. JAK2V617F mutation is ubiquitously present in splanchnic vein thrombosis accompanying myeloproliferative syndromes.
    Kanellopoulou T; Alexopoulou A; Koskinas J
    Aliment Pharmacol Ther; 2011 Jun; 33(12):1382-3. PubMed ID: 21569067
    [No Abstract]   [Full Text] [Related]  

  • 24. [The clinical implication of JAK2 mutation expression in patients with myeloproliferative disorders].
    Fei HR; Zhang R; Chen SN; Pan JL; Cen JN; Xue YQ
    Zhonghua Nei Ke Za Zhi; 2007 Apr; 46(4):271-3. PubMed ID: 17637260
    [TBL] [Abstract][Full Text] [Related]  

  • 25. JAK2V617F allele burden in patients with myeloproliferative neoplasms.
    Alshemmari SH; Rajaan R; Ameen R; Al-Drees MA; Almosailleakh MR
    Ann Hematol; 2014 May; 93(5):791-6. PubMed ID: 24362471
    [TBL] [Abstract][Full Text] [Related]  

  • 26. JAK2V617F mutation as a marker of a latent myeloproliferative disorder in a patient with Budd-Chiari syndrome and factor V Leiden mutation.
    Plumé G; Vayá A; Ferrando F; Mira Y; Orbis F
    Thromb Haemost; 2007 Sep; 98(3):681-2. PubMed ID: 17849060
    [No Abstract]   [Full Text] [Related]  

  • 27. [A novel quantitative JAK2V617F detection kit: prospective clinical performance study comparing MPN patients and healthy subjects].
    Kirito K; Koike M; Noguchi M; Kizaki M; Katayama N; Sugimoto Y; Dobashi N; Usui N; Komatsu N
    Rinsho Ketsueki; 2018; 59(6):669-674. PubMed ID: 29973441
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [High resolution melting analysis for detecting of JAK2V617F mutation in patients with myeloproliferative neoplasms].
    Chen HH; Yang JL; Lu HF; Zhou WJ; Yao F; Deng L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Feb; 22(1):112-6. PubMed ID: 24598662
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Progress of study on JAK2V617F mutation in myeloproliferative neoplasm].
    Chen YX; Li Y; Zhang LY; Liu B
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Oct; 19(5):1329-33. PubMed ID: 22040998
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Tyrosine kinase JAK2V617F mutation in human myeloproliferative disorders].
    Xu YY; Li HM; Li XJ; Yang L; Hu DM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Jun; 17(3):541-4. PubMed ID: 19549360
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical and laboratory significance of defective P2Y(12) pathway function in patients with myeloproliferative neoplasms: a pilot study.
    Chang H; Shih LY; Michelson AD; Dunn P; Frelinger AL; Wang PN; Kuo MC; Lin TL; Wu JH; Tang TC
    Acta Haematol; 2013; 130(3):181-7. PubMed ID: 23751441
    [TBL] [Abstract][Full Text] [Related]  

  • 32. JAK2V617F prevalence and allele burden in non-splanchnic venous thrombosis in the absence of overt myeloproliferative disorder.
    Pardanani A; Lasho TL; Schwager S; Finke C; Hussein K; Pruthi RK; Tefferi A
    Leukemia; 2007 Aug; 21(8):1828-9. PubMed ID: 17460706
    [No Abstract]   [Full Text] [Related]  

  • 33. A highly specific q-RT-PCR assay to address the relevance of the JAK2WT and JAK2V617F expression levels and control genes in Ph-negative myeloproliferative neoplasms.
    Fantasia F; Di Capua EN; Cenfra N; Pessina G; Mecarocci S; Rago A; Cotroneo E; Busanello A; Equitani F; Lo-Coco F; Nervi C; Cimino G
    Ann Hematol; 2014 Apr; 93(4):609-16. PubMed ID: 24173087
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Clinical significance of the quantification of JAK2V617F allele burden in classical Ph-negative myeloproliferative neoplasms].
    Kerguelén Fuentes AE; Hernández-Maraver D; Lombardia L; Canales Albendea MA; Rodriguez de la Rúa A
    Med Clin (Barc); 2012 Oct; 139(9):373-8. PubMed ID: 22743278
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A report on the co-occurrence of JAK2V617F and CALR mutations in myeloproliferative neoplasm patients.
    Xu N; Ding L; Yin C; Zhou X; Li L; Li Y; Lu Q; Liu XL
    Ann Hematol; 2015 May; 94(5):865-7. PubMed ID: 25366168
    [No Abstract]   [Full Text] [Related]  

  • 36. Molecular genetic tests for JAK2V617F, Exon12_JAK2 and MPLW515K/L are highly informative in the evaluation of patients suspected to have BCR-ABL1-negative myeloproliferative neoplasms.
    dos Santos MT; Mitne-Neto M; Miyashiro K; Chauffaille Mde L; Rizzatti EG
    J Clin Pathol; 2014 Feb; 67(2):176-8. PubMed ID: 23986553
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Two-round allele specific-polymerase chain reaction: a simple and highly sensitive method for JAK2V617F mutation detection.
    Kannim S; Thongnoppakhun W; Auewarakul CU
    Clin Chim Acta; 2009 Mar; 401(1-2):148-51. PubMed ID: 19135044
    [TBL] [Abstract][Full Text] [Related]  

  • 38. JAK2V617F mutation and myeloproliferative disorders in splanchnic vein thrombosis.
    Qi X; Hu F; Yang Z; Han G; Fan D
    Aliment Pharmacol Ther; 2011 Feb; 33(4):495-6; author reply 496-7. PubMed ID: 21235599
    [No Abstract]   [Full Text] [Related]  

  • 39. [Quantification of JAK2V617F mutational burden in chronic myeloproliferative neoplasms].
    Alvarez-Larrán A
    Med Clin (Barc); 2012 Oct; 139(9):393-4. PubMed ID: 22784403
    [No Abstract]   [Full Text] [Related]  

  • 40. [The discovery of JAK2 mutation has changed the diagnostic criteria of myeloproliferative neoplasms].
    Zhu P
    Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(25):1729-31. PubMed ID: 19035079
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.